Q3 2020 Sales Performance
Expected costs and savings under Major Restructuring
Programmes
£bn
Date
Announced
2019 Average Rates
Cumulative
Actuals to
2018
2019
2020
2021
2022
2023
Actuals
Projected 1
Combined
Integration &
Savings
2
3.9
4.2
4.3
2015
Total charges
5.2
0.1
0.1
Restructuring
Programme 3
2018
Cash payments
3.6
0.3
0.1
Savings 2
0.2
0.4
0.5
Restructuring
Q2'18
Total charges
0.4
0.8
0.4
0.2
Programme
(incl. Tesaro)
Cash payments
0.0
0.2
0.3
0.2
0.1
Synergies 2
0.2
0.4
0.5
Consumer JV
Dec-18
Total charges
0.3
0.5
0.1
0.1
Cash payments
0.2
0.4
0.1
0.0
Savings 2
0.1
0.3
0.7
0.8
Separation
Preparation
Programme 4
Feb-20
Total charges
Cash payments
0.9
0.9
0.6
0.0
0.5
0.7
0.4
0.0
1 All expectations and targets regarding future performance should be read together with the "Outlook assumptions and cautionary statement" sections of the Fourth Quarter 2019 Results Announcement and the
cautionary statement slide included with this presentation.
2 Savings and synergies shown are cumulative for the programme to date throughout the table
3 The Combined Integration and Restructuring programme is substantially complete, therefore GSK will cease external reporting of total costs and benefits for this programme from 2020 onward.
4 Does not include additional one-time costs to prepare Consumer Healthcare for separation, estimated at £600-700m, excluding transaction costs
83
83
gskView entire presentation